Skip to main content
. Author manuscript; available in PMC: 2013 Jan 1.
Published in final edited form as: Biol Blood Marrow Transplant. 2012 Jan;18(1 Suppl):S46–S52. doi: 10.1016/j.bbmt.2011.10.021

Figure 1.

Figure 1

Effect of etanercept on survival in post-HCT patients with subacute lung injury. A) Overall 5-year survival by pulmonary function testing defect. Patients with an obstructive defect (solid line) had a 5-year survival of 67% compared to 44% in those with a restrictive lung defect (dashed line) (p=0.19). B) Overall 5-year survival by response to therapy. Patients who responded to etanercept therapy (solid line) had a 5-year survival of 90% compared to 55% in patients who failed to respond (dashed line) (p=0.07). (Figures re-printed with permission, Biol Blood and Marrow Trans).